# Delfi Diagnostics
> Delfi Diagnostics is a biotechnology company developing high-performance, low-cost liquid biopsy tests for the early detection of cancer. The company utilizes a proprietary platform called fragmentomics, which applies machine learning to analyze patterns of DNA fragments in the bloodstream. By focusing on the structural biology of the genome rather than specific mutations, Delfi aims to make cancer screening more accessible and scalable globally.
- URL: https://optimly.ai/brand/delfi-diagnostics
- Slug: delfi-diagnostics
- BAI Score: 72/100
- Archetype: Challenger
- Category: Biotechnology
- Last Analyzed: April 10, 2026
## Competitors
- Guardant Health (https://optimly.ai/brand/guardant-health)
## Buyer Intent Signals
Problems: Standard Standard of Care Screening: Physicians rely on standard screening methods like colonoscopies or low-dose CT scans (LDCT) which are invasive or have lower compliance. | Wait-and-See Approach: Monitoring symptoms or waiting for clinical presentations, which often results in late-stage diagnosis. | Tissue Biopsy: Traditional tissue biopsies which require invasive surgical procedures to sample a tumor.
Solutions: What is fragmentomics in cancer detection? | liquid biopsy for lung cancer screening | Johns Hopkins cancer detection spinoffs | cheapest multi-cancer early detection test | FDA approved liquid biopsy for early detection
---
## Full Details / RAG Data
### Overview
Delfi Diagnostics is listed in the AI Directory.
Delfi Diagnostics is a biotechnology company developing high-performance, low-cost liquid biopsy tests for the early detection of cancer. The company utilizes a proprietary platform called fragmentomics, which applies machine learning to analyze patterns of DNA fragments in the bloodstream. By focusing on the structural biology of the genome rather than specific mutations, Delfi aims to make cancer screening more accessible and scalable globally.
### Metadata
| Field        | Value |
|--------------|-------|
| Name         | Delfi Diagnostics |
| Slug         | delfi-diagnostics |
| URL          | https://optimly.ai/brand/delfi-diagnostics |
| BAI Score    | 72/100 |
| Archetype    | Challenger |
| Category     | Biotechnology |
| Last Analyzed | April 10, 2026 |
| Last Updated | 2026-04-30T21:45:26.123Z |
### Verified Facts
- Founded: 2019
- Headquarters: Baltimore, Maryland, USA
### Competitors
| Name | Profile |
|------|---------|
| Guardant Health | https://optimly.ai/brand/guardant-health |
### Buyer Intent Signals
#### Problems this brand solves
- Standard Standard of Care Screening: Physicians rely on standard screening methods like colonoscopies or low-dose CT scans (LDCT) which are invasive or have lower compliance.
- Wait-and-See Approach: Monitoring symptoms or waiting for clinical presentations, which often results in late-stage diagnosis.
- Tissue Biopsy: Traditional tissue biopsies which require invasive surgical procedures to sample a tumor.
#### Buyers search for
- What is fragmentomics in cancer detection?
- liquid biopsy for lung cancer screening
- Johns Hopkins cancer detection spinoffs
- cheapest multi-cancer early detection test
- FDA approved liquid biopsy for early detection
### Links
- Canonical page: https://optimly.ai/brand/delfi-diagnostics
- JSON endpoint: /brand/delfi-diagnostics.json
- LLMs.txt: /brand/delfi-diagnostics/llms.txt